Iron deficiency syndromes and iron-restricted erythropoiesis (CME)

Transfusion

Volumn 52, Issue 7, 2012, Pages 1584-1592

  Goodnough, Lawrence Tim ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; HEPCIDIN; IRON; TRANSFERRIN;

BLOOD TRANSFUSION; ERYTHROCYTE; ERYTHROPOIESIS; HEMOCHROMATOSIS; HEREDITARY HEMOLYTIC ANEMIA; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON STORAGE; IRON THERAPY; NUTRITIONAL DEFICIENCY; PHLEBOTOMY; PHYSICIAN; REVIEW;

AGED; ANTIMICROBIAL CATIONIC PEPTIDES; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; HUMANS; INFANT; INFLAMMATION; IRON; IRON METABOLISM DISORDERS; MALE; MIDDLE AGED; SYNDROME;

EID: 84863807852     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03495.x     Document Type: Review

References (66)

1. Goodnough LT, Shander A,. Blood management. Arch Pathol Lab Med 2007; 131: 695-701.
2. Stoltzfus RJ,. Iron-deficiency anemia: reexamining the nature and magnitude of the public health problem. Summary: implications for research and programs. J Nutr 2001; 131: 697S-700S.
3. Guyatt GH, Patterson C, Ali M, Singer J, Levine M, Turpie I, Meyer R,. Diagnosis of iron-deficiency anemia in the elderly. Am J Med 1990; 88: 205-9.
4. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC,. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004; 104: 2263-8.
5. Ferrucci L, Semba RD, Guralnik JM, Ershler WB, Bandinelli S, Patel KV, Sun K, Woodman RC, Andrews NC, Cotter RJ, Ganz T, Nemeth E, Longo DL,. Proinflammatory state, hepcidin, and anemia in older persons. Blood 2010; 115: 3810-6.
6. Goodnough LT,. The new age of iron: evaluation and management of iron-restricted erythropoiesis. Semin Hematol 2009; 46: 325-7.
7. Annibale B, Capurso G, Chistolini A, D'Ambra G, DiGiulio E, Monarca B, DelleFave G,. Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms. Am J Med 2001; 111: 439-45.
8. Acher PL, Al-Mishlab T, Rahman M, Bates T,. Iron-deficiency anaemia and delay in the diagnosis of colorectal cancer. Colorectal Dis 2003; 5: 145-8.
9. Raje D, Mukhtar H, Oshowo A, Ingham Clark C,. What proportion of patients referred to secondary care with iron deficiency anemia have colon cancer? Dis Colon Rectum 2007; 50: 1211-4.
10. Auerbach M, Pappadakis JA, Bahrain H, Auerbach SA, Ballard H, Dahl NV,. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol 2011; 86: 860-2.
11. Goodnough LT, Nemeth E, Ganz T,. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010; 116: 4754-61.
12. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J,. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-7.
13. Auerbach M,. Ferumoxytol as a new, safer, easier-to-administer intravenous iron: yes or no? Am J Kidney Dis 2008; 52: 826-9.
14. Finch CA,. Erythropoiesis, erythropoietin, and iron. Blood 1982; 60: 1241-6.
15. Crosby WH,. The metabolism of hemoglobin and bile pigment in hemolytic disease. Am J Med 1955; 18: 112-22.
16. Hillman RS, Henderson PA,. Control of marrow production by the level of iron supply. J Clin Invest 1969; 48: 454-60.
17. Crosby WH,. Treatment of haemochromatosis by energetic phlebotomy; one patient's response to the letting of 55 litres of blood in 11 months. Br J Haematol 1958; 4: 82-8.
18. Coleman DH, Stevens AR Jr, Dodge HT, Finch CA,. Rate of blood regeneration after blood loss. Arch Intern Med 1953; 92: 341-9.
19. Finch CA, Huebers H,. Perspectives in iron metabolism. N Engl J Med 1982; 306: 1520-8.
20. Goodnough LT, Skikne B, Brugnara C,. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96: 823-33.
21. American Association of Blood Banks. Standards for blood banks and transfusion services. 27th ed. Bethesda (MD): American Association of Blood Banks Press; 2011.
22. Kickler TS, Spivak JL,. Effect of repeated whole blood donations on serum immunoreactive erythropoietin levels in autologous donors. JAMA 1988; 260: 65-7.
23. Goodnough LT, Brittenham GM,. Limitations of the erythropoietic response to serial phlebotomy: implications for autologous blood donor programs. J Lab Clin Med 1990; 115: 28-35.
24. Goodnough LT, Rudnick S, Price TH, Ballas SK, Collins ML, Crowley JP, Kosmin M, Kruskall MS, Lenes BA, Menitove JE, Silberstein LE, Smith KJ, Wallas KH, Abels R, Von Tress M,. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 1989; 321: 1163-8.
25. Goodnough LT, Price TH, Parvin CA, Friedman KD, Vogler WR, Khan N, Sacher R, Johnston M, Wissel M, Ciavarella D,. Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy. Br J Haematol 1994; 87: 695-9.
26. Brugnara C, Colella GM, Cremins J, Langley RC Jr, Schneider TJ, Rutherford CJ, Goldberg MA,. Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med 1994; 123: 660-7.
27. Goodnough LT, Price TH, Friedman KD, Johnston M, Ciavarella D, Khan N, Sacher R, Vogler WR, Wissel M, Abels RI,. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion 1994; 34: 66-71.
28. Sans T, Bofil C, Joven J, Clivillé X, Simõ JM, Llobet X, Perõ A, Galbany J,. Effectiveness of very low doses of subcutaneous recombinant human erythropoietin in facilitating autologous blood donation before orthopedic surgery. Transfusion 1996; 36: 822-6.
29. Mercuriali F, Inghilleri G, Biffi E, Colotti MT, Vinci A, Oriani G,. Epoetin alfa in low hematocrit patients to facilitate autologous blood donation in total hip replacement: a randomized, double-blind, placebo-controlled, dose-ranging study. Acta Haematol 1998; 100: 69-76.
30. Goodnough LT, Price TH, Rudnick S, Soegiarso RW,. Preoperative red cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion 1992; 32: 441-5.
31. Brugnara C, Chambers LA, Malynn E, Goldberg MA, Kruskall MS,. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood 1993; 81: 956-64.
32. Goodnough LT, Price TH, Parvin CA,. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Clin Med 1995; 126: 57-64.
33. Goodnough LT, Verbrugge D, Marcus RE, Goldberg V,. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell volume expansion in autologous blood donors for elective orthopedic operation. J Am Coll Surg 1994; 179: 171-6.
34. Eschbach JW, Haley NR, Egrie JC, Adamson JW,. A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects. Kidney Int 1992; 42: 407-16.
35. Mercuriali F, Zanella A, Barosi G, Inghilleri G, Biffi E, Vinci A, Colotti MT,. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion 1993; 33: 55-60.
36. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ,. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19: 1599-605.
37. Goodnough LT, Marcus RE,. Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox Sang 1998; 75: 128-33.
38. Biesma DH, Kraaijenhagen RJ, Poortman J, Marx JJ, van de Wiel A,. The effect of oral iron supplementation on erythropoiesis in autologous blood donors. Transfusion 1992; 32: 162-5.
39. Weisbach V, Skoda P, Rippel R, Lauer G, Glaser A, Zingsem J, Zimmermann R, Eckstein R,. Oral or intravenous iron as an adjuvant to autologous blood donation in elective surgery: a randomized, controlled study. Transfusion 1999; 39: 465-72.
40. Kasper SM, Lazansky H, Stark C, Klimek M, Laubinger R, Borner U,. Efficacy of oral iron supplementation is not enhanced by additional intravenous iron during autologous blood donation. Transfusion 1998; 38: 764-70.
41. Skikne BS, Cook JD,. Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med 1992; 120: 746-51.
42. Heiss MM, Tarabichi A, Delanoff C, Allgayer H, Jauch KW, Hernandez-Richter T, Mempel W, Beck KG, Schildberg FW, Messmer K,. Perisurgical erythropoietin application in anemic patients with colorectal cancer: a double-blind randomized study. Surgery 1996; 119: 523-7.
43. Biesma DH, Van de Wiel A, Beguin Y, Kraaijenhagen RJ, Marx JJ,. Erythropoietic activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy. Eur J Clin Invest 1994; 24: 426-32.
44. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR,. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-42.
45. Ganz T,. Hepcidin and iron regulation, 10 years later. Blood 2011; 117: 4425-33.
46. Nemeth E, Ganz T,. The role of hepcidin in iron metabolism. Acta Haematol 2009; 122: 78-86.
47. Andrews NC,. Forging a field: the golden age of iron biology. Blood 2008; 112: 219-30.
48. Finberg KE,. Iron-refractory iron deficiency anemia. Semin Hematol 2009; 46: 378-86.
49. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M,. Immunoassay for human serum hepcidin. Blood 2008; 112: 4292-7.
50. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman R, Maxwell PH, Choi P,. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010; 95: 505-8.
51. Nemeth E,. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol 2010; 2010: 750643.
52. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S,. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006; 108: 3730-5.
53. Tanno T, Miller JL,. Iron loading and overloading due to ineffective erythropoiesis. Adv Hematol 2010; 2010: 358283.
54. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, Johnson RS,. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117: 1926-32.
55. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T,. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-6.
56. Weiss G, Goodnough LT,. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-23.
57. Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, Winters A, Juan T, Li H, Begley CG, Molineux G,. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010; 115: 3616-24.
58. Young B, Zaritsky J,. Hepcidin for clinicians. Clin J Am Soc Nephrol 2009; 4: 1384-7.
59. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, Sonnweber T, Eberwein L, Witcher DR, Murphy AT, Wroblewski VJ, Wurz E, Datz C, Weiss G,. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009; 113: 5277-86.
60. Zhang DL, Hughes RM, Ollivierre-Wilson H, Ghosh MC, Rouault TA,. A ferroportin transcript that lacks an iron-responsive element enables duodenal and erythroid precursor cells to evade translational repression. Cell Metab 2009; 9: 461-73.
61. Keel SB, Abkowitz JL,. The microcytic red cell and the anemia of inflammation. N Engl J Med 2009; 361: 1904-6.
62. Bonnar J, Goldberg A, Smith JA,. Do pregnant women take their iron? Lancet 1969; 1: 457-8.
63. Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, Lundin J, Lärfars G, Osterborg A,. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21: 627-32.
64. Bastit L, Vandebroek A, Altintas S, Gaede B, Pintér T, Suto TS, Mossman TW, Smith KE, Vansteenkiste JF,. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26: 1611-8.
65. Jurado RL,. Iron, infections, and anemia of inflammation. Clin Infect Dis 1997; 25: 888-95.
66. Bishu K, Agarwal R,. Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 2006; 1 Suppl 1: S19-23.